Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment

(2015) Alberto M. Martelli et al.   Oncotarget

The Role of Lipids in the Control of Autophagy

(2013) Claudia Dall'Armi et al.   CURRENT BIOLOGY

A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse

(2013) S Park et al.   LEUKEMIA

Updates of mTOR Inhibitors

(2012) Hongyu Zhou et al.   Anti-Cancer Agents in Medicinal Chemistry

The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia

(2012) Anthony V. Moorman   BLOOD REVIEWS

The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo

(2012) Hui Ren et al.   CANCER LETTERS

Dual Targeting of the Akt/mTOR Signaling Pathway Inhibits Castration-Resistant Prostate Cancer in a Genetically Engineered Mouse Model

(2012) N. Floc'h et al.   CANCER RESEARCH

Advances in the molecular pathobiology of B-lymphoblastic leukemia

(2012) Yi Zhou et al.   HUMAN PATHOLOGY

Autophagy Promotes Intracellular Degradation of Type I Collagen Induced by Transforming Growth Factor (TGF)-β1

(2012) Sung Il Kim et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors

(2012) C Fialin et al.   LEUKEMIA

Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia

(2012) C Simioni et al.   LEUKEMIA

PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response

(2012) C Shepherd et al.   LEUKEMIA

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells

(2012) Nicole Grabinski et al.   Molecular Cancer

Multi-Level Targeting of the Phosphatidylinositol-3-Kinase Pathway in Non-Small Cell Lung Cancer Cells

(2012) Christopher R. Zito et al.   PLoS One

Next-generation Akt inhibitors provide greater specificity: effects on glucose metabolism in adipocytes

(2011) Shixiong Tan et al.   BIOCHEMICAL JOURNAL

Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma

(2011) Dan Liu et al.   CANCER

Endogenous knockdown of survivin improves chemotherapeutic response in ALL models

(2011) D J Morrison et al.   LEUKEMIA

Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts

(2011) G Fuka et al.   LEUKEMIA

Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia

(2011) C Evangelisti et al.   LEUKEMIA

Differential requirements for c-Myc in chronic hematopoietic hyperplasia and acute hematopoietic malignancies in Pten-null mice

(2011) J Zhang et al.   LEUKEMIA

The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia

(2011) L Willems et al.   LEUKEMIA

Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway

(2011) A M Martelli et al.   LEUKEMIA

AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications

(2011) C Grimaldi et al.   LEUKEMIA

Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells

(2011) A Silva et al.   LEUKEMIA

Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia

(2011) Naoto Morishita et al.   PEDIATRIC BLOOD & CANCER

Phosphorylated mTOR Expression is Associated with Poor Prognosis for Patients with Esophageal Squamous Cell Carcinoma

(2010) Kotaro Hirashima et al.   ANNALS OF SURGICAL ONCOLOGY

Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways

(2010) D. C. Hassane et al.   BLOOD

The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells

(2010) Catrin Schult et al.   BMC CANCER

Cytogenetics in pre-B and B-cell acute lymphoblastic leukemia: a study of 208 patients diagnosed between 1981 and 2008

(2010) Etienne De Braekeleer et al.   CANCER GENETICS AND CYTOGENETICS

Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma

(2010) S. A. Aziz et al.   CLINICAL CANCER RESEARCH

The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia

(2010) P. Saunders et al.   HAEMATOLOGICA

Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia

(2010) Camilla Evangelisti et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Revealing the role of TEL/AML1 for leukemic cell survival by RNAi-mediated silencing

(2010) M Zaliova et al.   LEUKEMIA

Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies

(2010) N Chapuis et al.   LEUKEMIA

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

(2010) T E Witzig et al.   LEUKEMIA

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

(2010) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia

(2009) Roman Crazzolara et al.   Autophagy

The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma

(2009) Ledu Zhou et al.   MEDICAL ONCOLOGY

Antiproliferative effect of rapamycin on human T-cell leukemia cell line Jurkat by cell cycle arrest and telomerase inhibition

(2008) Yan-min ZHAO et al.   ACTA PHARMACOLOGICA SINICA

AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines

(2008) D. S. Levy et al.   BLOOD

Autophagy in aging, disease and death: the true identity of a cell death impostor

(2008) B Levine et al.   CELL DEATH AND DIFFERENTIATION

Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease

(2008) Valerie I. Brown et al.   IMMUNOLOGIC RESEARCH

Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells

(2008) C Nishioka et al.   LEUKEMIA